產(chǎn)品[
CRL-1993 HMy2.CIR 人B**母細(xì)胞
]資料
如果您對(duì)該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
CRL-1993 HMy2.CIR 人B**母細(xì)胞
產(chǎn)品型號(hào):
CRL-1993
產(chǎn)品廠商:
美國標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無相關(guān)文檔
簡單介紹
CRL-1993 HMy2.CIR 人B**母細(xì)胞，ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞|；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和Z優(yōu)培養(yǎng)條件！
CRL-1993 HMy2.CIR 人B**母細(xì)胞
的詳細(xì)介紹
CRL-1993 HMy2.CIR 人B**母細(xì)胞
|
|
CRL-1993?
|
|
|
|
|
HMy2.CIR [C1R, HMy2.C1R]
|
|
|
P Cresswell
|
|
Biosafety Level:
|
2 [Cells contain Eptein-Barr Viral DNA sequences ]
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
suspension
|
|
|
Homo sapiens (human)
|
|
|
lymphoblast
|
|
|
Cell Type: B lymphoblast;
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
Amelogenin: X
CSF1PO: 6,10
D13S317: 11,13
D16S539: 9,13
D5S818: 10,13
D7S820: 7,12
THO1: 8
TPOX: 8
vWA: 17
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
|
|
|
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10(5) viable cells/ml.
Interval: Maintain between 2 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days
|
|
|
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
|
|
|
parental cell line:ATCC CRL-1621
derivative:ATCC CRL-2369
derivative:ATCC CRL-2370
derivative:ATCC CRL-2371
|
|
|
23312: Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
|
|
